{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:52:16Z","timestamp":1792849936297,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Health Economics"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.jhealeco.2007.10.007","type":"journal-article","created":{"date-parts":[[2007,12,5]],"date-time":"2007-12-05T19:35:58Z","timestamp":1196883358000},"page":"175-200","source":"Crossref","is-referenced-by-count":68,"title":["The risk we bear: The effects of review speed and industry user fees on new drug safety"],"prefix":"10.1016","volume":"27","author":[{"given":"Mary K.","family":"Olson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhealeco.2007.10.007_bib1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.socscimed.2005.01.004","article-title":"A comparative analysis of drug safety withdrawals in the UK and US (1971\u20131992): implications for current regulatory thinking and policy","volume":"61","author":"Abraham","year":"2005","journal-title":"Social Science and Medicine"},{"issue":"1","key":"10.1016\/j.jhealeco.2007.10.007_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0009-9236(95)90078-0","article-title":"Drug safety discontinuations in the U.K., the U.S. and Spain from 1974\u20131993: a regulatory perspective","volume":"58","author":"Bakke","year":"1995","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib3","series-title":"Pharmacoepidemiology","first-page":"125","article-title":"The spontaneous reporting system in the United States","author":"Baum","year":"1994"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib4","doi-asserted-by":"crossref","unstructured":"Begosh, A., Goldsmith, J., Hass, E., Lutter, R., Nardinelli, C., Vernon, J., December 2006. Black Box Warnings and Drug Safety: Examining the Determinants and Timing of FDA Warning Labels. NBER Working Paper 12803.","DOI":"10.3386\/w12803"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nrd1774","article-title":"Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates","volume":"4","author":"Berndt","year":"2005","journal-title":"Nature Reviews: Drug Discovery"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib6","series-title":"Regression Analysis of Count Data","author":"Cameron","year":"1998"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib7","unstructured":"Carpenter, D., January 30, 2004. \u201cPerspective: Defending Submission-year Analyses of New Drug Approvals\u201d Health Affairs Web Exclusive."},{"key":"10.1016\/j.jhealeco.2007.10.007_bib8","series-title":"Pharmacoepidemiology","first-page":"1431","article-title":"Screening for unknown effects of newly marketed drugs","author":"Carson","year":"1994"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib9","unstructured":"Center for Drug Evaluation and Research, Food and Drug Administration, October 1996. The clinical impact of adverse event reporting. A MedWatch Continuing Education Article."},{"key":"10.1016\/j.jhealeco.2007.10.007_bib46","unstructured":"Food and Drug Administration, 1997. Final Performance Report, Prescription Drug User Fee Act of 1992, FY 1997 Report to Congress. Available online at: http:\/\/www.fda.gov\/ope\/pdufa\/report97\/pdufa97.htm."},{"key":"10.1016\/j.jhealeco.2007.10.007_bib10","unstructured":"Center for Drug Evaluation and Research, Food and Drug Administration, 2000. CDER 2000 Report to the Nation: Improving Public Health Through Human Drugs."},{"key":"10.1016\/j.jhealeco.2007.10.007_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/pds.744","article-title":"Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980\u201399","volume":"11","author":"Cross","year":"2002","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib13","series-title":"Impure Science: AIDS, Activism, and the Politics of Knowledge","author":"Epstein","year":"1996"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib14","unstructured":"Food and Drug Administration, March 2005. FY 2004 PDUFA Financial Report, Required by the Prescription Drug User Fee Act of 1992 as Amended by the Food and Drug Modernization Act of 1997 and the Prescription Drug User Fee Amendments of 2002."},{"issue":"18","key":"10.1016\/j.jhealeco.2007.10.007_bib15","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.281.18.1728","article-title":"The safety of newly approved medicines: do recent market removals mean there is a problem?","volume":"281","author":"Friedman","year":"1999","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib16","unstructured":"Government Accountability Office, 2002. Food and Drug Administration: Effect of User Fees on Drug Approval Times, Withdrawals, and Other Agency Activities. GAO-02-958."},{"key":"10.1016\/j.jhealeco.2007.10.007_bib17","series-title":"The Regulation of Pharmaceuticals: Balancing the Benefits and the Risks","author":"Grabowski","year":"1983"},{"issue":"2","key":"10.1016\/j.jhealeco.2007.10.007_bib18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1377\/hlthaff.25.2.452","article-title":"The quantity and quality of worldwide new drug introductions, 1982\u20132003","volume":"25","author":"Grabowski","year":"2006","journal-title":"Health Affairs"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib19","unstructured":"Grabowski, H., Wang, Y.R., February 2006b. Determinants of New Drug Safety in the United States, 1993\u20132003, Mimeo."},{"key":"10.1016\/j.jhealeco.2007.10.007_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9343(02)01529-2","article-title":"Troglitazone-induced liver failure: a case study","volume":"114","author":"Graham","year":"2003","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib21","unstructured":"Institute of Medicine, September 2006. The future of drug safety: promoting and protecting the health of the public. Final Report of the Committee on the Assessment of the U.S. Drug Safety System. National Academy Press, Washington, D.C."},{"key":"10.1016\/j.jhealeco.2007.10.007_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/009286150303700403","article-title":"The new drug approvals of 1999, 2000, and 2001: drug development trends after the Passage of the Prescription Drug User Fee Act of 1992","volume":"37","author":"Kaitin","year":"2003","journal-title":"Drug Information Journal"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/009286150003400101","article-title":"The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era","volume":"34","author":"Kaitin","year":"2000","journal-title":"Drug Information Journal"},{"issue":"1","key":"10.1016\/j.jhealeco.2007.10.007_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00045391-199701000-00010","article-title":"The new drug approvals of 1993, 1994, and 1995: trends in drug development","volume":"4","author":"Kaitin","year":"1997","journal-title":"American Journal of Therapeutics"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/j.1552-4604.1994.tb03975.x","article-title":"The new drug approvals of 1990, 1991, and 1992: trends in drug development","volume":"34","author":"Kaitin","year":"1994","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"21","key":"10.1016\/j.jhealeco.2007.10.007_bib26","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1001\/jama.1993.03500210065033","article-title":"Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems","volume":"269","author":"Kessler","year":"1993","journal-title":"Journal of the American Medical Associations"},{"issue":"17","key":"10.1016\/j.jhealeco.2007.10.007_bib27","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","article-title":"Timing of new black box warnings and withdrawals for prescription medications","volume":"287","author":"Lasser","year":"2002","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib28","series-title":"Measuring Capital in the New Economy","article-title":"Pharmaceutical knowledge-capital accumulation and longevity","author":"Lichtenberg","year":"2005"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib29","unstructured":"Moeller et al., 2001. MEPS Methodology Report 12, AHRQ."},{"issue":"11","key":"10.1016\/j.jhealeco.2007.10.007_bib30","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1056\/NEJMp058003","article-title":"What ails the FDA?","volume":"352","author":"Okie","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.jhealeco.2007.10.007_bib47","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1162\/105864097567138","article-title":"Firm Characteristics and the Speed of FDA Approval","volume":"6","author":"Olson","year":"1997","journal-title":"Journal of Economics & Management Strategy"},{"issue":"2","key":"10.1016\/j.jhealeco.2007.10.007_bib31","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1086\/368006","article-title":"Pharmaceutical policy and the safety of new drugs","volume":"45","author":"Olson","year":"2002","journal-title":"Journal of Law and Economics"},{"issue":"3","key":"10.1016\/j.jhealeco.2007.10.007_bib32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1215\/03616878-29-3-397","article-title":"Managing delegation with user fees: reducing delay in new drug review","volume":"29","author":"Olson","year":"2004","journal-title":"Journal of Health Politics, Policy, and Law"},{"issue":"6","key":"10.1016\/j.jhealeco.2007.10.007_bib33","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhealeco.2004.03.007","article-title":"Are novel drugs more risky for patients than less novel drugs?","volume":"23","author":"Olson","year":"2004","journal-title":"Journal of Health Economics"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib34","unstructured":"Olson, M.K., January 30, 2004c. \u201cPerspective: Explaining Reductions In FDA Drug Review Times: PDUFA Matters\u201d Health Affairs Web Exclusive."},{"key":"10.1016\/j.jhealeco.2007.10.007_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1086\/467136","article-title":"The health effects of mandatory prescriptions","volume":"30","author":"Peltzman","year":"1987","journal-title":"Journal of Law and Economics"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib36","doi-asserted-by":"crossref","unstructured":"Philipson, T., Berndt, E.R., Gottschalk, A., Strobeck, M.W., 2005. Addressing the safety and efficacy of the FDA: the case of the Prescription Drug User Fee Acts. Working Paper No. W11724. National Bureau of Economic Research, Cambridge, MA.","DOI":"10.3386\/w11724"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib37","series-title":"The Politics of Regulation","article-title":"The food and drug administration","author":"Quirk","year":"1980"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib39","series-title":"Pharmacoepidemiology","author":"Strom","year":"1994"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib40","doi-asserted-by":"crossref","unstructured":"Thompson, L., September\u2013October 2000. \u201cUser Fees for Faster Drug Reviews: Are They Helping or Hurting the Public Health?\u201d FDA Consumer Magazine.","DOI":"10.1037\/e543562006-006"},{"issue":"5","key":"10.1016\/j.jhealeco.2007.10.007_bib45","first-page":"1","article-title":"Drug safety withdrawals in the US not linked to speed of FDA approval","volume":"7","author":"Tufts Center for the Study of Drug Development","year":"2005","journal-title":"Tufts CSDD Impact Report"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib41","doi-asserted-by":"crossref","unstructured":"Vernon, J, Golect, J., Lutter, R., Nardinelli, C., September 2006. FDA new drug approval times, Prescription Drug User Fees and R&D spending. AEI-Brooking Joint Center for Regulatory Studies. Working Paper 06-21.","DOI":"10.2139\/ssrn.931153"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib42","series-title":"Los Angeles Times","article-title":"How a new policy led to seven deadly drugs","author":"Willman","year":"2000"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib43","series-title":"Econometric Analysis of Cross Section and Panel Data","author":"Wooldridge","year":"2002"},{"key":"10.1016\/j.jhealeco.2007.10.007_bib44","first-page":"261","article-title":"The Prescription Drug User Fee Act: is a faster FDA always a better FDA?","volume":"60","author":"Zelenay","year":"2005","journal-title":"Food Drug and Law Journal"}],"container-title":["Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167629607000732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167629607000732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,5]],"date-time":"2019-05-05T15:35:56Z","timestamp":1557070556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167629607000732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0167629607000732"],"URL":"https:\/\/doi.org\/10.1016\/j.jhealeco.2007.10.007","relation":{},"ISSN":["0167-6296"],"issn-type":[{"value":"0167-6296","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}